Rxadvance Pbm India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 29.71%
- Profit Growth 27.65%
- Ebitda 30.51%
- Net Worth 33.79%
- Total Assets 34.82%
About Rxadvance Pbm India
Rxadvance Pbm India Private Limited (RPIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 06 July 2015 (Nine years and seven months 7 days old ). Its registered office is in Gautam Buddha Nagar, Uttar Pradesh, India.
The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Bijendra Malik, Ravi Ika, and Madusudhana Narahari serve as directors at the Company.
Company Details
-
Location
Gautam Buddha Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U72300UP2015FTC071836
-
Company No.
071836
-
Company Classification
Private Limited Foreign Company Incorporated In India
-
Incorporation Date
06 Jul 2015
-
Date of AGM
25 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Rxadvance Pbm India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bijendra Malik
|
Director | 06-Jul-2015 | Current |
|
Ravi Ika
|
Director | 06-Jul-2015 | Current |
|
Madusudhana Narahari
|
Director | 04-May-2023 | Current |
Financial Performance of Rxadvance Pbm India.
Rxadvance Pbm India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.71% increase. The company also saw a substantial improvement in profitability, with a 27.65% increase in profit. The company's net worth Soared by an impressive increase of 33.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rxadvance Pbm India?
In 2023, Rxadvance Pbm India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rxadvance Pbm India?
Rxadvance Pbm India has a workforce of 156 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rxadvance Pbm India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rxadvance Pbm India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
